The Social Responsibility Performance Of Health Care Enterprises Is Facing New Challenges, And There Is A Big Gap Between The Sub Sectors

On September 26, at the "2020 China's big health industry summit - value reconstruction of big health industry under the public health crisis" sponsored by the 21st century economic report, the 21st century Industry Research Institute released the social responsibility report of China's health and medical listed companies in 2020.

The 21st century industrial research institute once again conducted health "scanning" on more than 300 listed companies in the big health industry. This year's social responsibility related indicators include economic benefits, environmental protection, product quality and safety, fair competition, employee compensation, social welfare, and social responsibility report. Different from the past, this year's epidemic situation has become the largest variable. In order to evaluate enterprises more objectively, the report takes the social responsibility performance of enterprises in the epidemic situation as an important indicator.

Although there is a significant gap between the pharmaceutical industry and other industries in terms of social responsibility, it can be found that there is still a gap between the pharmaceutical industry and other industries in terms of social responsibility.

In fact, after the transformation and pain of the first two years, from 2019 to 2020, a number of heavy policies affecting China's pharmaceutical industry have gradually become normalized, superimposed with the sudden impact of the new epidemic, profoundly reshaping the development of China's pharmaceutical industry. After this "epidemic", it has become the consensus of the society in the post epidemic era to make the biomedical health industry bigger and stronger. With the coming of the epidemic, only with strong innovation and research strength of detection reagents, drugs and vaccines can we be invincible in major public health emergencies.

There is a big gap between sub sectors

This year's social responsibility related indicators include economic benefits, environmental protection, product quality and safety, fair competition, employee compensation, social welfare, and social responsibility reporting. Among them, environmental protection, product quality and safety, and whether social responsibility reports have been issued are relatively important, with a high weight, with a full score of 20 points and the remaining four items with a full score of 10 points. The total score of the seven indicators was 100 points.

According to the statistical results, the top ten enterprises with total scores are pharmaceutical enterprises, and Jiangzhong Pharmaceutical Co., Ltd., which ranks first, and Shanghai pharmaceutical, which ranks third, have a full score of 20 points in terms of social responsibility report. In terms of social welfare, Fosun Pharmaceutical and Kelun pharmaceutical ranked fourth and fifth with full score of 10. However, among the bottom 10 enterprises, 6 are pharmaceutical enterprises, and Guonong science and technology ranked at the bottom of the sample database, which shows that although pharmaceutical enterprises have excellent achievements in social responsibility, there is still a large gap between enterprises.

In terms of social responsibility report, 2 pharmaceutical enterprises scored full marks, and 134 enterprises got less than 10 points, accounting for 57.5% of the statistical data. In the medical service industry, the highest score of Chinese medicine was 19 points, with 36 enterprises with less than 10 points, accounting for 61% of the statistical data. In the medical device consumables industry, 9 enterprises scored 18 points, but 71 enterprises scored less than 10 points, accounting for 60.3% of the statistical data.

In other words, the industry ranking based on the highest score (the same score is based on the number of enterprises) is pharmaceutical enterprises < medical services < medical equipment consumables. If we take the proportion of enterprises with scores below 10 as the standard, the ranking is pharmaceutical enterprises < medical equipment consumables < medical services.

In terms of social welfare, 4 pharmaceutical enterprises got full score of 10, and 62 enterprises got less than 5 points, accounting for 26.6% of the statistical data. In the medical service industry, 2 enterprises got full marks, and 20 enterprises got less than 5 points, accounting for 33.9% of the statistical data. In the medical device consumables industry, one enterprise got full score, and 30 enterprises scored less than 5 points, accounting for 24.8% of the statistical data.

In terms of environmental protection, the highest score of pharmaceutical industry is 18 points (9 companies), and there are 60 enterprises with scores below 10 points, accounting for 25.8% of the statistical data. The highest score of the medical service industry is 16 points (1 company). There are 41 Enterprises with scores below 10 points, accounting for 69.5% of the statistical data. The highest score of medical device consumables industry is 18 points (5 companies), and there are 60 enterprises with scores below 10 points, accounting for 49.6% of the statistical data.

In the aspect of accepting administrative punishment or serious violation of regulations, three enterprises in the pharmaceutical industry have been subject to administrative punishment or warning. Two medical service companies have been subject to administrative punishment or warning. In the medical device consumables industry, one enterprise has been subject to administrative punishment for two times, and another enterprise has three violations.

Generally speaking, although the pharmaceutical industry is better than other industries, it is still in a relatively backward position in some indicators, and the gap between enterprises is quite obvious, so we should continue to strengthen the performance of social responsibility. Although the performance of the other industries is slightly lower than that of the pharmaceutical industry on the whole, they can also be in a leading position in some indicators. We should continue to maintain this advantage and continue to make efforts to lower ranking indicators to strengthen the implementation of corporate social responsibility.

Corporate social responsibility faces new challenges

From the above scoring, there is still a lot of room for improvement in social responsibility of Chinese health and medical listed companies.

At the same time, this year's new crown pneumonia epidemic has become the biggest "black swan" affecting global economic development. After this "epidemic", it has become the consensus of the society in the post epidemic era to make the health industry bigger and stronger. With the coming of the epidemic, only with strong innovation and research strength of detection reagents, drugs and vaccines can we be invincible in major public health emergencies.

Deng Honghui, deputy editor in chief of Nanfang finance and economics all media group, Secretary of the Party committee and chief editor of the 21st century newspaper, said in his speech that under the outbreak of the epidemic, the whole society is rethinking the "value of health", and the public's awareness of active health management has increased unprecedentedly, and the big health industry has received unprecedented attention. At the same time, it also brings many new changes to the big health industry, which will become an important driving force in the second half of the big health industry.

However, China's big health industry is still in the process of industrial structure adjustment and transformation, and the change of national macro policy has become the biggest variable affecting industrial development in recent years.

This year, the new policy of health care reform is still intensive and heavy. From the No.1 document of the State Food and Drug Administration of the people's Republic of China on the guiding principles of drug research and development and evaluation supported by real world evidence (Trial Implementation), to the promulgation of drug registration management measures and drug production supervision and management measures, from bulk purchase to normalization to dynamic adjustment of medical insurance catalogue, all of these indicate that the development environment of enterprises in the future will be more and more open, but the competition will also be more intense 。

This is still in the throes of industrial transformation and structural adjustment, how to better perform corporate social responsibility in the future will be a greater test. In this year's epidemic situation, the overall performance of enterprises in the big health industry was eye-catching. They not only actively donated money and materials, but also gave full play to their own professional expertise and advantages, and actively supported the society and the country in fighting against the epidemic, which fully demonstrated the responsibility and responsibility of enterprises.

Corporate social responsibility (CSR) represents that while operating the main business, managing the enterprise, creating profits and being responsible for the interests of shareholders, the enterprise should also shoulder the responsibility for employees, society and environment, including abiding by business ethics, production safety, occupational health, protecting the legitimate rights and interests of workers, and saving resources.

It is an important issue to measure whether an enterprise can develop healthily or not. It is also one of the core competitiveness for an enterprise to go further.

The 21st century economic report has been advocating and calling for medical and health enterprises to fulfill social responsibility. With such a view, China's health industry "sunshine" award 2020 will list social responsibility as the most important evaluation index. "Sunshine" award not only objectively and fairly selects the enterprises and individuals who have made achievements in product innovation, economic benefits and market performance, but also excavates and praises those enterprises and individuals who have made contributions to public welfare undertakings and adhere to professional ethics. The 21st century economic report strongly advocates and promotes the practice of "social responsibility" to become the professional starting line of each major health industry participant.